2012 Annual Meeting of the European Association for the Study of the Liver*

April 18-22, 2012; Barcelona, Spain
CCO's independent conference coverage of the 2012 Annual Meeting of the European Association for the Study of the Liver includes a CME-certified slideset with faculty analysis and a downloadable slideset that focuses on key issues highlighted at the conference.

Highlights From Barcelona 2012

Capsules

In this open-label, randomized phase II trial, the efficacy of 12 weeks of GS-7977 plus pegIFN/RBV combination therapy appeared to be comparable to that of 24 weeks of GS-7977 plus pegIFN/RBV combination therapy.

Released: April 20, 2012

PegIFN lambda-1a associated with fewer musculoskeletal events, influenzalike symptoms, and fewer hematologic adverse events.

Released: April 22, 2012

SVR rates typically 56% to 68%, with response rates up to 82% seen with this combination.

Released: April 22, 2012

Response to pegIFN/RBV lead-in therapy correlated with previous response and predicted SVR in previous pegIFN/RBV nonresponders retreated with boceprevir plus pegIFN/RBV.

Released: April 22, 2012

Treatment with tegobuvir and GS-9256 plus peginterferon/ribavirin produced very rapid HCV RNA suppression in treatment-naive patients with genotype 1 HCV; however, safety signals indicating that tegobuvir may be associated with pancytopenia when administered with another direct-acting antiviral agent plus peginterferon/ribavirin resulted in discontinuation of quadruple therapy in this trial.

Released: April 22, 2012

ABT-450/ritonavir plus ABT-072 plus ribavirin well tolerated through 12 weeks of treatment

Released: April 23, 2012

Despite lack of OS benefit, brivanib improved TTP, DCR, and ORR

Released: April 22, 2012

SVR rates lower (47%) in previous nonresponders to pegIFN/RBV, but no patients who completed treatment experienced virologic failure

Released: April 23, 2012

Interferon-free regiment produced a 77% SVR24 rate in difficult-to-treat patients with genotype 1b HCV infection

Released: April 23, 2012

In this randomized phase IIb trial, alisporivir with or without ribavirin maintained on-treatment virologic responses after early HCV RNA clearance, confirming that it has a high genetic barrier to resistance.

Released: April 23, 2012

Although low rates of SVR12 were demonstrated among patients infected with genotype 1a HCV, the regimen was well tolerated with no occurrence of serious adverse events.

Released: April 22, 2012

Safety, tolerability profiles similar for the 2 anemia management regimens

Released: April 22, 2012

Preliminary results from this ongoing randomized phase II trial demonstrate potent antiviral activity of 24 weeks of GS-5885, GS-9451, tegobuvir, and ribavirin, with higher SVR rates observed in the 90-mg GS-5885 dosing arm compared with the 30-mg GS-5885 arm.

Released: April 22, 2012

Daclatasvir plus GS-7977 associated with 100% rate of SVR4 among patients with genotype 1a/1b HCV infection and > 90% rate in patients with genotype 2 or 3 HCV infection in this phase IIa trial.

Released: April 22, 2012

SVR24 rates of up to 85% were seen in previously relapsed patients, up to 75% in patients with previous partial response, and up to 51% in previous null responders.

Released: April 20, 2012

In this multicenter cohort involving 28 patients with severe genotype 1 hepatitis C recurrence following liver transplantation, 56% to 70% of patients had undetectable HCV RNA following 8 weeks of treatment with boceprevir or telaprevir plus pegIFN/RBV (with or without 4-week pegIFN/RBV lead-in phase); however, patients experienced high rates of anemia and required frequent reductions in the dosage of calcineurin inhibitors.

Released: April 24, 2012

SVR12 rate was substantially higher with boceprevir plus peginterferon/ribavirin vs peginterferon/ribavirin alone in HIV/HCV-coinfected patients receiving stable antiretroviral therapy who were naive to HCV therapy.

Released: April 23, 2012

In this examination of data from phase III telaprevir trials, no patients with HCV RNA > 1000 IU/mL at Week 4 or Week 12 achieved sustained virologic response.

Released: April 22, 2012

Miravirsen monotherapy over 4 weeks yielded dose-dependent HCV RNA reductions without evidence of viral resistance in treatment-naive patients chronically infected with genotype 1 HCV; no dose-limiting toxicities were observed.

Released: April 22, 2012

Rates of serious adverse events were markedly higher in this study population than in phase III trials of telaprevir- and boceprevir-based therapy for patients with genotype 1 HCV infection.

Released: April 20, 2012
Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Abbott
Boehringer Ingelheim Pharmaceuticals, Inc.
Genentech
Gilead Sciences
Vertex

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?